SCHEMBL3863484

SCHEMBL3863484

Cc1ccc2c(c1)c1cc(-c3sc4ccccc4c3C)c(=O)n(C)c1n2C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.39
▸ TDP1 Q9NUW8 3/20 0.39
▸ MAPT P10636 2/20 0.39
▸ PKM P14618 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ PGR P06401 1/20 0.39
▸ RORA P35398 1/20 0.39
▸ RORC P51449 1/20 0.39
▸ RORB Q92753 1/20 0.39
▸ APAF1 O14727 1/20 0.39
▸ IDO1 P14902 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ MCL1 Q07820 1/20 0.39
▸ NTRK1 P04629 1/20 0.36
▸ PMM2 O15305 3/20 0.35
▸ MPI P34949 3/20 0.35
▸ PHOSPHO1 Q8TCT1 3/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3443982 0.81 MAPT (0.39) KDM4ETDP1MAPTPKMRAB9A
SCHEMBL3863768 0.79 MEN1 (0.41) KDM4ETDP1MAPTRAB9AHTT
SCHEMBL3867984 0.78 HSD17B10 (0.46) KDM4ETDP1MAPTPKMRAB9A
SCHEMBL3859813 0.75 CCNE2 (0.43) KDM4ETDP1MAPTPKMRAB9A
SCHEMBL3444792 0.75 PKM (0.42) KDM4ETDP1MAPTPKMRAB9A
SCHEMBL2384727 0.74 KDM4E (0.49) KDM4ETDP1MAPTPKMRAB9A
SCHEMBL2385054 0.74 MAPT (0.46) KDM4ETDP1MAPTPKMRAB9A
SCHEMBL3446228 0.73 BRD4 (0.45) KDM4ETDP1MAPTPKMRAB9A
Hydrochloric Acid SCHEMBL3444816 0.72 BRD4 (0.44) KDM4ETDP1MAPTPKMRAB9A
SCHEMBL13116677 0.72 KDM4E (0.48) KDM4ETDP1MAPTPKMRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042924-A1 Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics SANOFI-AVENTIS (FR) 2009-02-12 — — US claimed
US-7456193-B2 Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-11-25 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042924-A1 Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics PNPO, DPYD, PDXK KDM4E 2743/4885TDP1 904/4885MAPT 4064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback